1. Clinical & Scientific Overview
Oral Potassium Chloride & Potassium Citrate Solutions (TIP-MED-000202, Reference Code [10.18]) is classified under
Vitamins, Minerals & Nutrition — CKD-MBD & Electrolyte Binders/Buffers (Ch 10) as a Electrolyte Replenishment & Urinary Alkalinising / Citrate-Chelation Agents (Schedule H | NLEM 2022 | HIGH-ALERT).
Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.18], p. 135): Potassium Chloride (KCl) Oral Liquid: Potklor (Walter Bushnell), Keylyte, Kesol (20 mEq K+ per 15 mL). Potassium Citrate Oral Liquid: Potrate, Kcit, Urokit (Potassium Citrate 1100 mg = 10 mEq K+ per 5 mL) — Strengths & Dosage Forms: Potassium Chloride Oral Solution: 1.5 g KCl / 15 mL (= 20 mEq K+ and 20 mEq Cl- per 15 mL tablespoon). Potassium Citrate Oral Solution: 1100 mg K-Citrate / 5 mL (= 10 mEq K+ per 5 mL teaspoon); ER Tablets: 5 mEq, 10 mEq
Potassium Chloride Oral Solution: 1.5 g KCl / 15 mL (= 20 mEq K+ and 20 mEq Cl- per 15 mL tablespoon). Potassium Citrate Oral Solution: 1100 mg K-Citrate / 5 mL (= 10 mEq K+ per 5 mL teaspoon); ER Tablets: 5 mEq, 10 mEq
3. Mechanism of Action & Pharmacodynamics
Electrolyte Replenishment & Urinary Alkalinising / Citrate-Chelation Agents (Schedule H | NLEM 2022 | HIGH-ALERT) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutrition — CKD-MBD & Electrolyte Binders/Buffers (Ch 10): clinical efficacy is mediated via Electrolyte Replenishment & Urinary Alkalinising / Citrate-Chelation Agents (Schedule H | NLEM 2022 | HIGH-ALERT) for Potassium Chloride (KCl): Prevention and treatment of hypokalaemia (Serum K+ <3.5 mEq/L, especially with Loop/Thiazide diuretics, vomiting, or diarrhoea, or in patients on Digoxin). Potassium Citrate: Calcium oxalate/uric acid nephrolithiasis (kidney stones) and renal tubular acidosis (RTA) with hypokalaemia.
4. Therapeutic Indications & Evidence-Supported Uses
- Potassium Chloride (KCl): Prevention and treatment of hypokalaemia (Serum K+ <3
- 5 mEq/L, especially with Loop/Thiazide diuretics, vomiting, or diarrhoea, or in patients on Digoxin)
- Potassium Citrate: Calcium oxalate/uric acid nephrolithiasis (kidney stones) and renal tubular acidosis (RTA) with hypokalaemia
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Potassium Chloride Oral Liquid: Prophylaxis: 20 mEq (15 mL) PO OD; Treatment of Hypokalaemia: 20 mEq (15 mL) PO BD–QID (40–80 mEq/day) titrated by Serum K+. Potassium Citrate Oral Liquid (Renal Calculi / RTA): 10–20 mEq (5–10 mL) PO BD–TDS after meals
Administration & Meal Timing: MANDATORY DILUTION & POST-MEAL RULE: ALWAYS dilute every 5–15 mL dose of Potassium Chloride or Potassium Citrate liquid in AT LEAST 1 FULL GLASS (200–250 mL) OF COLD WATER OR JUICE, and sip slowly IMMEDIATELY AFTER A FULL MEAL! Never drink undiluted KCl/K-Citrate syrup directly from the spoon! | Immediately After Meals, diluted in 1 full glass of water (BD–TDS)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: CONTRAINDICATED if eGFR <30 mL/min unless correcting documented severe hypokalaemia under inpatient biochemical monitoring! Hepatic: Caution in cirrhotic ascites on Spironolactone
Renal: CONTRAINDICATED if eGFR <30 mL/min unless correcting documented severe hypokalaemia under inpatient biochemical monitoring! Hepatic: Caution in cirrhotic ascites on Spironolactone
Renal: CONTRAINDICATED if eGFR <30 mL/min unless correcting documented severe hypokalaemia under inpatient biochemical monitoring! Hepatic: Caution in cirrhotic ascites on Spironolactone
7. Contraindications, Precautions & High-Risk Warnings
- HIGH-ALERT HYPERKALAEMIA & LASA DISTINCTION: Distinguish Potklor / KCl and Potrate / Kcit (both contain high loads of Potassium [K+]!) from Citralka (Disodium Hydrogen Citrate — contains Sodium [Na+]!). Potassium Chloride & Potassium Citrate are STRICTLY CONTRAINDICATED in Hyperkalaemia (Serum K+ >5.0 mEq/L), severe CKD (eGFR <30 mL/min), Addison's disease, and concomitant Spironolactone, Eplerenone, Amiloride, or Co-trimoxazole!
Key Clinical Precautions: Renal: CONTRAINDICATED if eGFR <30 mL/min unless correcting documented severe hypokalaemia under inpatient biochemical monitoring! Hepatic: Caution in cirrhotic ascites on Spironolactone
8. Adverse Effects Profile
- Nausea, vomiting, epigastric burning, abdominal cramps, diarrhoea, salty/bitter metallic taste (all minimised by diluting in 250 mL cold water and taking after a full meal!)
- LIFE-THREATENING HYPERKALAEMIA (Serum K+ >=6.0 mEq/L -> ascending muscle weakness/flaccid paralysis, bradycardia, peaked T-waves, ventricular fibrillation, and sudden cardiac arrest!), gastric ulceration
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- LETHAL HYPERKALAEMIA COMBINATIONS: Concomitant Potassium-Sparing Diuretics (Spironolactone, Eplerenone), ACE Inhibitors (Ramipril, Enalapril), ARBs (Telmisartan, Losartan), ARNI (Sacubitril/Valsartan), NSAIDs, Trimethoprim (Co-trimoxazole), Heparin, or Cyclosporine/Tacrolimus can cause rapid fatal hyperkalaemic cardiac arrest!
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: THREE VITAL COUNTER RULES: (1) Always mix your measured 5–15 mL spoonful of Potklor or Potrate in ONE FULL GLASS (200 mL) of water and sip it slowly right after a meal — never swallow the syrup neat!; (2) Confirm you are NOT taking Spironolactone (Aldactone) or Telmisartan/Ramipril without regular blood potassium tests; (3) Stop immediately and seek emergency care if you feel unusual leg weakness, tingling around the lips, or a slow/irregular pulse
- Meal & Clock Timing Instruction: MANDATORY DILUTION & POST-MEAL RULE: ALWAYS dilute every 5–15 mL dose of Potassium Chloride or Potassium Citrate liquid in AT LEAST 1 FULL GLASS (200–250 mL) OF COLD WATER OR JUICE, and sip slowly IMMEDIATELY AFTER A FULL MEAL! Never drink undiluted KCl/K-Citrate syrup directly from the spoon! (Immediately After Meals, diluted in 1 full glass of water (BD–TDS))
- Missed Dose Protocol: Take after next meal if remembered; NEVER double a dose of Potassium!
- Geriatric Dispensing Pearl: Very high risk of fatal hyperkalaemia in older adults with declining GFR or on RAAS blockers — always verify recent Serum K+ and eGFR before dispensing
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Potassium Chloride Oral Solution: 1.5 g KCl / 15 mL (= 20 mEq K+ and 20 mEq Cl- per 15 mL tablespoon). Potassium Citrate Oral Solution: 1100 mg K-Citrate / 5 mL (= 10 mEq K+ per 5 mL teaspoon); ER Tablets: 5 mEq, 10 mEq
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.18] (p. 135)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [10.20]-C128 Sodium Zirconium Cyclosilicate — Non-Calcium Polymeric Phosphate Binder & Gastrointestinal Potassi
- [10.14] Calcitriol & Alfacalcidol (Active Vitamin D Metabolites for CKD-MBD & Hypoparathyroidism) — Active 1,25-Dihydroxycholecalciferol & 1-Alpha-Hydroxycholecalcif
- [10.19] Sodium Bicarbonate (Oral Enteric/Uncoated for CKD Metabolic Acidosis) — Systemic Alkalinising Buffer for Chronic Kidney Disease Metabolic
- [10.20] Sevelamer Carbonate & Calcium Polystyrene Sulfonate / Sodium Zirconium Cyclosilicate — Non-Calcium Polymeric Phosphate Binder & Gastrointestinal Potassi